tert-butyl 4-(2-aminopyrimidin-5-yl)piperidine-1-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: tert-butyl 4-(2-aminopyrimidin-5-yl)piperidine-1-carboxylate
• 英文别名: Tert-butyl 4-(2-aminopyrimidin-5-YL)piperidine-1-carboxylate
• 化学式: C₁₄H₂₂N₄O₂
• 分子量: 278.354
• InChiKey: QSGYUDUYAHNSAH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  81.3
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  N-Boc-1,2,5,6-四氢吡啶-4-硼酸频哪醇酯 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 palladium 10% on activated carbon 、 氢气 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 乙醇 、 水 为溶剂， 80.0 ℃ 、101.33 kPa 条件下， 生成 tert-butyl 4-(2-aminopyrimidin-5-yl)piperidine-1-carboxylate
  参考文献：
  名称：

  [EN] CERTAIN PROTEIN KINASE INHIBITORS
  [FR] INHIBITEURS DE CERTAINES PROTÉINES KINASES

  摘要：

  提供了某些CDK4/6抑制剂、药物组成和使用方法。

  公开号：

  WO2017114351A1

文献信息

• BENZONITRILE DERIVATIVES AS KINASE INHIBITORS
  申请人：Hoelzemann Guenter

  公开号：US20140228340A1

  公开（公告）日：2014-08-14

  Compounds of the formula I, in which R 1 , R 2 , X and Y have the meanings indicated in Claim 1 , are inhibitors of TBK1 and IKKε and can be employed, inter alia, for the treatment of cancer and inflammatory diseases.

  式I中的化合物，其中R1、R2、X和Y具有权利要求1中指示的含义，是TBK1和IKKε的抑制剂，可用于治疗癌症和炎症性疾病。
• [EN] CDK INHIBITORS<br/>[FR] INHIBITEURS DE CDK
  申请人：RHIZEN PHARMACEUTICALS AG

  公开号：WO2022113003A1

  公开（公告）日：2022-06-02

  The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof as cyclin-dependent kinase inhibitors (one or more of CDK1, CDK2, CDK4, and CDK6), methods of preparing them, and pharmaceutical compositions containing them. The compounds of the present invention are useful in the treatment, prevention and/or amelioration of diseases or disorders associated with one or more of CDK1, CDK2, CDK4, and CDK6.

  本发明提供了式（I）化合物及其药学上可接受的盐作为细胞周期素依赖性激酶抑制剂（其中一个或多个为CDK1，CDK2，CDK4和CDK6），制备它们的方法以及含有它们的药物组合物。本发明的化合物在治疗、预防和/或改善与CDK1、CDK2、CDK4和CDK6中的一个或多个相关的疾病或疾病方面是有用的。
• Heterocyclic compounds as kinase inhibitors
  申请人：NUVATION BIO INC.

  公开号：US11174252B2

  公开（公告）日：2021-11-16

  Heterocyclic compounds of Formula (J) as CDK4 or CDK6 or other CDK inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.

  提供了作为 CDK4 或 CDK6 或其他 CDK 抑制剂的式 (J) 的杂环化合物。这些化合物可用作治疗疾病的药物，尤其可用于肿瘤学。
• Kinase Inhibitor And Use Thereof
  申请人：XUANZHU PHARMA CO., LTD.

  公开号：US20160332989A1

  公开（公告）日：2016-11-17

  The invention relates to a CDK4/6 kinase inhibitor, or a pharmaceutically acceptable salt, ester, or solvate thereof, or their isomers; a pharmaceutical formulation, pharmaceutical composition and kit comprising said CDK4/6 kinase inhibitor, or a pharmaceutically acceptable salt, ester, or solvate thereof, or their isomers, and use of said CDK4/6 kinase inhibitor, or a pharmaceutically acceptable salt, ester, or solvate thereof, or their isomers. For example, the compounds of the invention are useful for reducing or inhibiting the activity of CDK4/6 kinase in a cell, and/or treating and/or preventing a cancer-related disease mediated by CDK4/6 kinase.
• HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS
  申请人：GIRAFPHARMA LLC

  公开号：US20190248774A1

  公开（公告）日：2019-08-15

  Heterocyclic compounds as CDK4 or CDK6 or other CDK inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.